Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781351 | 0.92 | CNR2 (1.00) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5776929 | 0.91 | CNR2 (0.84) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5782588 | 0.91 | CNR2 (1.00) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5781144 | 0.90 | CNR2 (0.88) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5083343 | 0.89 | CNR2 (1.00) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL3380605 | 0.89 | CNR2 (1.00) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5777553 | 0.89 | CNR2 (0.84) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5778784 | 0.88 | CNR2 (0.88) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5781741 | 0.88 | CNR2 (1.00) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5781217 | 0.88 | CNR2 (0.83) | CNR2CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534687-B1 | 2-PHENYLAMINO-4-TRIFLUOROMETHYL-5-(BENZYL- OR PYRIDIN-4-YLMETHYL)CARBAMOYLPYRIMIDINE DERIVATIVES AS SELECTIVE CB2 CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-09-27 | — | — | EP | claimed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1736470-A2 | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060247261-A1 | Pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| EP-1534687-B1 | 2-PHENYLAMINO-4-TRIFLUOROMETHYL-5-(BENZYL- OR PYRIDIN-4-YLMETHYL)CARBAMOYLPYRIMIDINE DERIVATIVES AS SELECTIVE CB2 CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247261-A1 | Pyrimidine compounds | CNR2, CNR1, P2RX5 | CNR2 1/4885CYP2C9 1163/4885CYP2C19 919/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | CNR2 1/4885CYP2C9 2242/4885CYP2C19 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.